{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:20:07Z","timestamp":1786994407032,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.msard.2021.102769","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T02:38:49Z","timestamp":1610937529000},"page":"102769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis\u2013A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"49","author":[{"given":"Halina","family":"Bartosik-Psujek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Kaczy\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"G\u00f3recka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5450-4480","authenticated-orcid":false,"given":"Miros\u0142aw","family":"Rolka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142","family":"W\u00f3jcik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Zi\u0119ba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Kaczor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.102769_bib0001","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2021.102769_bib0002","first-page":"529","article-title":"Efficacy of teriflunomide treatment in achieving no evidence of disease activity over a period of 6 months to 2 years in the TEMSO study","volume":"21","author":"Chan","year":"2015","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2021.102769_bib0003","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1517\/14656566.2013.754012","article-title":"Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis","volume":"14","author":"Comi","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.msard.2021.102769_bib0004","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418791103","article-title":"Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod","volume":"11","author":"Diem","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2021.102769_bib0005","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.102769_bib0006","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s13311-017-0573-4","article-title":"Cladribine to treat relapsing forms of multiple sclerosis","volume":"14","author":"Giovannoni","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2021.102769_bib0007","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/WCO.0000000000000561","article-title":"Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm","volume":"31","author":"Giovannoni","year":"2018","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2021.102769_bib0008","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.msard.2017.07.011","article-title":"A brief history of NEDA","volume":"20","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.102769_bib0009","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.102769_bib0010","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(11)70023-0","article-title":"Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis","volume":"10","author":"Giovannoni","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2021.102769_bib0011","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.102769_bib0012","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1177\/1352458518771875","article-title":"Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: a post hoc analysis of the CLARITY study","volume":"25","author":"Giovannoni","year":"2019","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2021.102769_bib0013","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.102769_bib0014","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1474-4422(09)70021-3","article-title":"Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study","volume":"8","author":"Havrdova","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2021.102769_bib0015","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/ene.13272","article-title":"Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies","volume":"24","author":"Havrdova","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2021.102769_bib0016","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/ene.13669","article-title":"No evidence of disease activity\u2019 - is it an appropriate surrogate in multiple sclerosis?","volume":"25","author":"Hegen","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2021.102769_bib0017","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.bjpt.2018.12.006","article-title":"Understanding and interpreting confidence and credible intervals around effect estimates","volume":"23","author":"Hespanhol","year":"2019","journal-title":"Braz. J. Phys. Ther."},{"key":"10.1016\/j.msard.2021.102769_bib0018","series-title":"Cochrane Handbook for Systematic Reviews of Interventions. Version 5.2.0. The Cochrane Collaboration","author":"Higgins","year":"2017"},{"key":"10.1016\/j.msard.2021.102769_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin. Trials"},{"key":"10.1016\/j.msard.2021.102769_bib0020","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/1352458515616701","article-title":"Inclusion of brain volume loss in a revised measure of \"no evidence of disease activity\u2019 (NEDA-4) in relapsing-remitting multiple sclerosis","volume":"22","author":"Kappos","year":"2016","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2021.102769_bib0021","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00415-015-7978-y","article-title":"Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis","volume":"263","author":"Kappos","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.102769_bib0022","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.102769_bib0023","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102769_bib0024","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","article-title":"Cladribine: mode of action and implications for treatment of multiple sclerosis","volume":"34","author":"Leist","year":"2011","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.msard.2021.102769_bib0025","first-page":"80","article-title":"Leczenie stwardnienia rozsianego","volume":"12","author":"Losy","year":"2016","journal-title":"Zalecenia Polskiego Towarzystwa Neurologicznego. Polski Przegl\u0105d Neurologiczny."},{"key":"10.1016\/j.msard.2021.102769_bib0026","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.msard.2017.12.016","article-title":"The evolution of \u201cNo Evidence of Disease Activity\u201d in multiple sclerosis","volume":"20","author":"Lu","year":"2018","journal-title":"Mult. Scler. Relat. Dis."},{"key":"10.1016\/j.msard.2021.102769_bib0027","doi-asserted-by":"crossref","first-page":"e69775","DOI":"10.1371\/journal.pone.0069775","article-title":"Modelling the dynamics of an experimental host-pathogen microcosm within a hierarchical Bayesian framework","volume":"8","author":"Lunn","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2021.102769_bib0028","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.102769_bib0029","first-page":"426","article-title":"Reviewing the unmet needs of patients with multiple sclerosis","volume":"8","author":"Mehr","year":"2015","journal-title":"Am. Health Drug Benefits"},{"key":"10.1016\/j.msard.2021.102769_bib0030","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/ene.13536","article-title":"ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis","volume":"25","author":"Montalban","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2021.102769_bib0032","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1007\/s12325-014-0167-z","article-title":"No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis","volume":"31","author":"Nixon","year":"2014","journal-title":"Adv. Ther."},{"key":"10.1016\/j.msard.2021.102769_bib0033","first-page":"18","article-title":"Spatial distribution of white matter degenerative lesions and cognitive dysfunction in relapsing-remitting multiple sclerosis patients","volume":"53","author":"Nowaczyk","year":"2019","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.msard.2021.102769_bib0034","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O\u2019Connor","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.102769_bib0035","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria\u201d","volume":"58","author":"Polman","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.102769_bib0036","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102769_bib0037","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","article-title":"Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort","volume":"72","author":"Rotstein","year":"2015","journal-title":"Jama Neurol"},{"key":"10.1016\/j.msard.2021.102769_bib0038","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1080\/03007995.2017.1407303","article-title":"Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis","volume":"34","author":"Siddiqui","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.msard.2021.102769_bib0039","first-page":"1622","volume":"391","author":"Thompson","year":"2018","journal-title":"Mult. Scler. Lancet"},{"key":"10.1016\/j.msard.2021.102769_bib0040","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5603\/PJNNS.a2019.0010","article-title":"Early predictors of injectable disease modifying drugs suboptimal response based on clinical and radiological data assessment in Polish Multiple Sclerosis patients","volume":"53","author":"Wawrzyniak","year":"2019","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.msard.2021.102769_bib0041","first-page":"534","article-title":"Efficacy of teriflunomide treatment in achieving no evidence of disease activity in the TEMSO long-term extension study","volume":"21","author":"Wolinsky","year":"2015","journal-title":"Mult. Scler. J."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821000353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821000353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:56:24Z","timestamp":1761900984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821000353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":40,"alternative-id":["S2211034821000353"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.102769","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis\u2013A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.102769","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102769"}}